Skip to main content
Premium Trial:

Request an Annual Quote

Almac Gets CLIA OK for Lab

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Almac Diagnostics today said that it has received CLIA certification for a new lab it has opened to support its biomarker discovery and development strategy.

Craigavon, Northern Ireland-based Almac said that the lab will support its own needs as well as those of its pharmaceutical partners.

"We have come to a point where the biomarkers we have discovered and assays that we have developed are being used to stratify patients, enrich clinical trials, and impact patient treatment decisions," Paul Harkin, president and managing director of Almac’s Diagnostics business, said in a statement. "As such, CLIA is a key necessity for the processing of these samples."